Ipsen Overview
- Year Founded
-
1929
- Status
-
Public
- Employees
-
5,535
- Stock Symbol
-
IPN
- Investments
-
35
- Share Price
-
$183.87
- (As of Friday Closing)
Ipsen General Information
Description
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
Contact Information
Website
www.ipsen.comCorporate Office
- 70 rue Balard
- 75015 Paris
- France
Corporate Office
- 70 rue Balard
- 75015 Paris
- France
Ipsen Timeline
Ipsen Stock Performance
As of 13-Nov-2026, Ipsen’s stock price is $183.87. Its current market cap is $15.2B with 82.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $183.87 | $185.28 | $135.54 - $203.45 | $15.2B | 82.4M | 103K | $7.26 |
Ipsen Financials Summary
As of 30-Jun-2026, Ipsen has a trailing 12-month revenue of $5.01B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 15,179,104 | 10,841,201 | 9,439,000 | 9,967,969 |
| Revenue | 5,005,891 | 4,432,162 | 3,867,962 | 3,577,774 |
| EBITDA | 1,714,902 | 1,075,328 | 914,157 | 1,210,842 |
| Net Income | 597,959 | 500,271 | 374,298 | 697,289 |
| Total Assets | 8,518,755 | 8,149,271 | 6,700,242 | 6,989,333 |
| Total Debt | 995,147 | 1,018,512 | 444,116 | 412,867 |
Ipsen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ipsen Comparisons
Industry
Financing
Details
Ipsen Competitors (45)
One of Ipsen’s 45 competitors is Biogen, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biogen | Formerly VC-backed | Cambridge, MA | ||||
| AbbVie | Corporation | North Chicago, IL | ||||
| Takeda Pharmaceutical | Corporation | Tokyo, Japan | ||||
| Biocon | Formerly PE-Backed | Bengaluru, India | ||||
| Novartis | Corporation | Basel, Switzerland |
Ipsen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ipsen Patents
Ipsen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202509237-D0 | Stabilised formulation | Pending | 11-Jun-2025 | ||
| AU-2025240177-A1 | Cell-based neurotoxin assay | Pending | 20-Mar-2024 | ||
| GB-202404021-D0 | Cell-based neurotoxin assay | Inactive | 20-Mar-2024 | ||
| WO-2025196445-A1 | Cell-based neurotoxin assay | Pending | 20-Mar-2024 | ||
| EP-4833510-A1 | A biosensor for real-time monitoring of clostridial neurotoxin production | Pending | 28-Dec-2023 | G01N33/542 |
Ipsen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ipsen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Ipsen Investments & Acquisitions (35)
Ipsen’s most recent deal was a Merger/Acquisition with Kartos Therapeutics for . The deal was made on 20-Aug-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Kartos Therapeutics | 20-Aug-2026 | Merger/Acquisition | Drug Discovery | ||
| Memo Therapeutics | 22-Jul-2026 | Merger/Acquisition | Drug Discovery | ||
| Simcere Zaiming (Global Rights for the Antibody-Drug Conjugate for Cancer in China) | 22-Dec-2025 | Corporate Asset Purchase | Buildings and Property | ||
| ImCheck Therapeutics | 15-Dec-2025 | Merger/Acquisition | Drug Discovery | ||
| Foreseen Biotech (Rights to Develop, Manufacture and Commercialize FS001) | 11-Jul-2024 | Corporate Asset Purchase | Buildings and Property |
Ipsen ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
22.02 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Ipsen Exits (9)
Ipsen’s most recent exit was on 16-May-2024 from Vitropep. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Vitropep | 16-May-2024 | Completed |
|
||
| Bakx | 18-Nov-2021 | Completed |
|
||
| Rhythm Pharmaceuticals | 16-Feb-2017 | Completed |
|
||
| Motus Therapeutics | 13-Aug-2015 | Completed |
|
||
| Rhythm Pharmaceuticals | 13-Aug-2015 | Later Stage VC | Completed |
|
Ipsen Affiliates
Subsidiaries (10)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Kartos Therapeutics | Redwood City, CA | 2018 | |
| ImCheck Therapeutics | Marseille, France | 2015 | |
| Memo Therapeutics | Zurich, Switzerland | 2012 | |
| Syntaxin | Abingdon, United Kingdom | 2005 | |
| Ipsen Poland | Warsaw, Poland | 2005 |
Ipsen FAQs
-
When was Ipsen founded?
Ipsen was founded in 1929.
-
Where is Ipsen headquartered?
Ipsen is headquartered in Paris, France.
-
What is the size of Ipsen?
Ipsen has 5,535 total employees.
-
What industry is Ipsen in?
Ipsen’s primary industry is Biotechnology.
-
Is Ipsen a private or public company?
Ipsen is a Public company.
-
What is Ipsen’s stock symbol?
The ticker symbol for Ipsen is IPN.
-
What is the current stock price of Ipsen?
As of 13-Nov-2026 the stock price of Ipsen is $183.87.
-
What is the current market cap of Ipsen?
The current market capitalization of Ipsen is $15.2B.
-
What is Ipsen’s current revenue?
The trailing twelve month revenue for Ipsen is $5.01B.
-
Who are Ipsen’s competitors?
Biogen, AbbVie, Takeda Pharmaceutical, Biocon, and Novartis are some of the 45 competitors of Ipsen.
-
What is Ipsen’s annual earnings per share (EPS)?
Ipsen’s EPS for 12 months was $7.26.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
